| Target Price | A$11.91 |
| Price | A$9.98 |
| Potential |
19.34%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Infratil 2026 .
The average Infratil target price is A$11.91.
This is
19.34%
register free of charge
A$13.69
37.21%
register free of charge
A$9.22
7.61%
register free of charge
|
|
| A rating was issued by 14 analysts: 10 Analysts recommend Infratil to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Infratil stock has an average upside potential 2026 of
19.34%
register free of charge
|
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion A$ | 3.33 | 3.00 |
| 22.69% | 10.46% | |
| EBITDA Margin | 26.53% | 29.54% |
| 1.75% | 11.34% | |
| Net Margin | -7.43% | 3.55% |
| 130.31% | 147.76% |
9 Analysts have issued a sales forecast Infratil 2026 . The average Infratil sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Infratil EBITDA forecast 2026. The average Infratil EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Infratil Analysts have issued a net profit forecast 2026. The average Infratil net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share A$ | -0.26 | 0.11 |
| 131.71% | 140.74% | |
| P/E | 90.95 | |
| EV/Sales | 5.39 |
9 Analysts have issued a Infratil forecast for earnings per share. The average Infratil EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


